Clinical Trial Update: Natalizumab Subcutaneous Immunogenicity and Safety Study [Phase 2]

View source ↗

Summary

Phase 2 study evaluating subcutaneous natalizumab for immunogenicity and safety has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: Biogen | Conditions: Relapsing Multiple Sclerosis | Phase 2 | Status: TERMINATED